Clinical research interleukin-18 expression and the response to treatment in patients with psoriasis

Archives of Medical Science

Volumn 7, Issue 4, 2011, Pages 713-719

  Rasmy, Hanaa ^a   Mikhael, Nancy ^a   Ismail, Somaia ^a  

^a NONE

Author keywords

Effect of therapy; Interleukins; Psoriasis; Real time PCR

Indexed keywords

BETAMETHASONE DIPROPIONATE; INTERLEUKIN 18; METHOTREXATE; STEROID;

ADULT; ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; KERATINOCYTE; MALE; PROTEIN EXPRESSION; PSORIASIS; SKIN BIOPSY; STEROID THERAPY; TREATMENT RESPONSE;

EID: 80052557727     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.24144     Document Type: Article

References (31)

1. Homey B, Dieu-Nosjean MC, Wiesenborn A, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000; 164: 6621-32. (Pubitemid 30408849)
2. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23. (Pubitemid 34073472)
3. Valdimarsson H, Baker BS, Jonsdottir I, Fry L. Psoriasis: A disease of abnormal keratinocyte proliferation induced by T-lymphocytes. Immunol Today 1986; 7: 256-9. (Pubitemid 17022412)
4. Barker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992; 126: 1-9.
5. Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, Kunikate T. Purification and characterization of the human interleukin-18 receptors. J Biol Chem 1997; 272: 25737-42. (Pubitemid 27438893)
6. Mastroeni P. Immunity to systemic salmonella infections. Curr Mol Med 2002; 2: 393-406. (Pubitemid 35452887)
7. Dinarello CA. Novel target for interleukin-18 binding protein. Ann Rheum Dis 2001; 60: 18-24.
8. Wigginton JM, Wiltrout RH. IL-12, IL-2 combination cytokine therapy for solid tumours: Translation from bench to beside. Expert Opin Biol Ther 2002; 2: 513-24. (Pubitemid 34716734)
9. Flisiak I, Klepacki A, Chodynicka B. Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity. Biomarkers 2006; 11: 194-200. (Pubitemid 43772016)
10. Kato T, Tsunemi Y, Saeki H, et al. Interferon-18 gene polymorphism -137 G/C is associated with susceptibility to psoriasis vulgaris but not with atopic dermatitis in Japanese patients. J Dermatol Sci 2009; 53: 162-3.
11. McKenzie RC, Boyce F, Forsey R, et al. Psoriatic skin expresses high levels of interleukin-18 (IL-18) and IL-18 receptor (IL-18R). Br J Dermatol 2000; 142: 618.
12. Ohta Y, Hamada Y, Katsuoka K. Expression of IL-18 in psoriasis. Arch Dermatol Res 2001; 293: 334-42. (Pubitemid 32757475)
13. McKenzie RC, Boyce F, Szepietowski JC, et al. Psoriatic epidermis expresses high levels of interleukin 18 (IL-18), IL-18 receptor mRNA and IL-18. Dermatol Klin 2002; 1-4: 17-23.
14. McKenzie RC, Sabin E, Szepietowski JC, Gracie JA, Forsy RJ, Howie S. Interferon gamma in keratinocytes in psoriasis. Eur J Dermatol 2003; 13: 315-6.
15. Fredriksson T, Pettersson U. Severe psoriasis - Oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44. (Pubitemid 8387357)
16. Marks R, Barton S, Shuttelworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol 1989; 125: 235-40. (Pubitemid 19070211)
17. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991; 124: 565-70.
18. Krueger J. What clinical trials teach us about the biology of psoriasis? Br J Dermatol 2006; 154: 461-6.
19. Yamanaka K, Clark R, Dowgiert R, et al. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res 2006; 12: 376-82. (Pubitemid 43166124)
20. Koizumi H, Sato-Matsumura KC, Nakamura H, et al. Distribution of IL-18 and IL-18 receptor in human skin: Various forms of IL-18 are produced in keratinocytes. Arch Dermatol Res 2001; 293: 325-33. (Pubitemid 32757474)
21. Chang C, Magracheva E, Kozlov S, et al. Crystal structure of interleukin-19 defines subfamily of helical cytokines. J Biol Chem 2003; 278: 3308-13. (Pubitemid 36801244)
22. Otkjaer K, Kragballe KV, Funding AT, et al. Interleukin 19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol 2005; 153: 911-8.
23. Piskin G, Tursen U, Sylva-Steenl RMR, Bos JD, Teunissen MBM. Clinical improvement in chronic plaque type poriasis lesion after narrow band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers IL-12 IL-18 and IL-23. Exp Dermatol 2004; 13: 764-72. (Pubitemid 39625223)
24. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Ann Rev Immunol 2001; 19: 423-74. (Pubitemid 32368042)
25. Kong J, Grando SA, Li YC. Regulation of IL-1 family cytokines IL-1alpha, IL-1 receptor antagonist, and IL-18 by 1,25-dihydroxyvitamin D in primary keratinocytes. J Immunol 2006; 176: 3780-7. (Pubitemid 43364026)
26. Smeltz RB. Profound enhancement of IL-12/IL-18 pathway of IFN-gamma section in human CD8+ memory T cell subset via IL-15. J Immunol 2007; 178: 4786-92. (Pubitemid 46595260)
27. Tak PP, Bacchi M, Bertolino M, Desson A. Pharma-cokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 2006; 31: 109-16. (Pubitemid 44166289)
28. Trinquet QV, Fogel P, Aldana-Jammayrac O, et al. Interleukin 19 gene expression profile in psoriasis: Anaylsis of impact of body site location and clinical severity. Br J Dermatol 2005; 152: 489-504. (Pubitemid 40547123)
29. Craven NM, Jackson CW, Kirby B, et al. Cytokine gene polymorphism in psoriasis. Br J Dermatol 2001; 144: 849-53.
30. Sampogna F, Tabolli S, Söderfeldt B, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006; 154: 844-9.
31. Chen WJ, Yang JY, Lin JH, et al. Nasopharyngeal shedding of severe acute respiratory syndrome associated corona virus is associated with genetic polymorphism. Clin Infect Dis 2006; 42: 1561-9.